Diabetes type 2 pandemic in 21st century

Bratislava Medical Journal

Volumn 111, Issue 3, 2010, Pages 134-137

  Ginter, E ^a   Simko, V ^b  

^a INST OF PREV AND CLINICAL MEDICINE   (Slovakia)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

Adipokines; Diabetes type 2; Free fatty acids; Increased prevalence; Leptin; Obesity

Indexed keywords

ADULT; AGED; ARTICLE; EPIDEMIC; FEMALE; HUMAN; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOPHYSIOLOGY;

ADULT; AGED; DIABETES MELLITUS, TYPE 2; DISEASE OUTBREAKS; FEMALE; HUMANS; MALE; MIDDLE AGED; OBESITY; YOUNG ADULT;

EID: 77953037470     PISSN: 00069248     EISSN: 13360345     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Diabetes Atlas, International Diabetes Federation, USA, 2007
2. Roglic G, Green A et al. Prevalence of diabetes. Estimates for the year 2000 and projection for 2030. Diabetes Care 2004,27: 1047-1053.
3. WHO. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Geneva, Switzerland, 2009.
4. CDC. Centres for Disease Control and Prevention. Atlanta, USA, 2007.
5. James WPT, Jackson-Leach R, Mhurdu CN et al. Overweight and Obesity. In Comparative Quantification of Health Risks. Eds. Ezzati M, Lopez AD, Rodgers A, Murray VJL. WHO, Geneva, 2003.
6. Cnop M. Fatty acids and glucolipotoxicity in the pathogenesis of Type 2 diabetes. Biochem Soc Trans 2008; 36 (Pt 3): 348-52.
7. Boden G. Obesity and free fatty acids. Endocrinol Metab Clin North Amer 2008; 37 (3): 635-646.
8. Boden G. Fatty acid-induced inflammation and insulin resistance in skeletal muscle and liver. Curr Diab Rep 2006; 6 (3): 177-181.
9. Wilding JP. The importance of free fatty acids in the development of Type 2 diabetes. Diabet Med 2007; 24 (9): 934-945.
10. Ioannidis I. The road from obesity to type 2 diabetes. Angiology 2008; 59 (2 Suppl): 39S-43S.
11. Rasouli N, Kern PA. Adipocytokines and the metabolic complicati ons of obesity. J Clin Endocrinol Metab 2008; 93 (11 Suppl 1): S64-73.
12. Guest CB, Park MJ, Johnson DR, Freund GG. The implication of proinflammatory cytokines in type 2 diabetes. Front Biosci 2008; 13: 5187-5194.
13. Keller U. From obesity to diabetes. Int J Vitam Nutr Res 2006; 76 (4): 172-177.
14. Antuna-Puente B, Feve B, Fellahi S, Bastard JP. Adipokines: the missing link between insulin resistance and obesity. Diabetes Metab 2008; 34(1): 2-11.
15. Martin SS, Qasim A, Reilly MP. Leptin resistance: a possible inter face of inflammation and metabolism in obesity-related cardiovascular disease. J Am Coll Cardiol 2008; 52 (15): 1201-1210.
16. Viollet B, Lantier L, Devin-Leclerc J et al. Targeting the AMPK pathway for the treatment of Type 2 diabetes. Front Biosci 2009; 14: 3380-3400.
17. Long YC, Zierath JR. AMP-activated protein kinase signaling in metabolic regulation. J Clin Invest 2006; 116 (7): 1776-1783.
18. Winder WW, Hardie DG. AMP-activated protein kinase, a meta bolic master switch: possible roles in Type 2 diabetes. Am J Physiol 1999; 277 (1 Pt), El-E10.
19. Hardie DG. AMPK: a key regulator of energy balance in the single cell and the whole organism. Int J Obes 2008; 32 Suppl 4: S7-12.
20. Ginter E, Simko V. Adult obesity at the beginning of the 21 st centu ry: epidemiology, pathophysiology and health risk. Bratisl Lek Listy 2008; 109 (5): 224-230.
21. Daniels SR, Jacobson MS, McCrindle BW et al. American Heart Association Childhood Obesity Research Summit: executive summary. Circulation 2009; 119 (15): 2114-2123.
22. Gordon-Larsen P, Boone-Heinon J, Sidney S et al. Active com muting and cardiovascular disease risk. The CARDIA study. Arch In tern Med 2009; 169: 1216-1223.
23. Ferencik M, Hulin I. Obesity, fatty tissue and inflammation. Med Monitor 2008; No 4: 1-6.
24. Mudaliar S, Henry RR. Incretin therapies: Effects beyond glyce-mic control. Am J Med 2009; 122: S25-S36.